Arvinas vs Aurinia Pharmaceuticals
Arvinas and Aurinia Pharmaceuticals are similar in size: $263m and $283m of revenue in their latest fiscal years. Aurinia Pharmaceuticals grew faster (20.4% against -0.3%). Aurinia Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 101.5% against -30.8%. Aurinia Pharmaceuticals carries less debt relative to equity (0.0% against 0.1%).
| Latest fiscal year | ArvinasARVN, 2025 | Aurinia PharmaceuticalsAUPH, 2025 |
|---|---|---|
| Revenue | $263m | $283m |
| Revenue growth | -0.3% | 20.4% |
| Net income | −$80.8m | $287m |
| Operating margin | -45.1% | 37.1% |
| Net margin | -30.8% | 101.5% |
| Return on equity | -16.2% | 59.9% |
| Free cash flow | −$276m | — |
| Cash | $143m | $80.2m |
| Total debt | $600,000 | $0 |
| Debt to equity | 0.1% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $91.9m | $98.2m |
| Employees | 246 | 128 |
| Market value | $462m | $2.23bn |
| Price vs our value range | — | Below our value range |
| Moat score | 9 (Weak) | 32 (Weak) |
| Insider trades, 12 months | 1 buys, 23 sales | 11 buys, 2 sales |